Dr. Edwin R. Ramirez, M.D.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
1801 Solar Dr Ste 251
Oxnard, CA 93030
Who else practices at this address →
Ventura County includes mental health (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 124
Licensed in California since 2007, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
CA license A101638 (first issued 2007; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- Community Memorial Hospital - Ventura Ventura, CA
- St Johns Regional Medical Center Oxnard, CA
- Adventist Health Simi Valley Simi Valley, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 124
- Services billed
- 401
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 88 | 58 |
| New patient office or other outpatient visit, 60-74 minutes | 43 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 22 | 19 |
| Simple measurement of pressure of urine flow in bladder | 19 | 18 |
| Complete ultrasound scan of pelvis | 19 | 13 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Oxnard, CA | 31 |
| Myrbetriq (mirabegron) Other prescribers in Oxnard, CA | 27 |
| Ibuprofen Other prescribers in Oxnard, CA | 22 |
| Ciprofloxacin Hcl Other prescribers in Oxnard, CA | 20 |
| Fluconazole Other prescribers in Oxnard, CA | 16 |
| Spironolactone Other prescribers in Oxnard, CA | 15 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Oxnard, CA | 15 |
| Solifenacin Succinate Other prescribers in Oxnard, CA | 14 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Oxnard, CA | 14 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Oxnard, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 20 payments worth $784 in total to this clinician.
| Sumitomo Pharma America, Inc. | $204 |
|---|---|
| Vertex Pharmaceuticals Incorporated | $193 |
| Karl Storz Endoscopy-america | $143 |
| Intuitive Surgical, Inc. | $130 |
| Femselect Inc. | $65.75 |
| Mayne Pharma Commercial LLC | $26.12 |
| Mimedx Group, Inc. | $22.63 |
| Food and Beverage | $784 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $53,199 in research payments for these studies, mostly to the institutions running them.
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Sumitomo Pharma America, Inc. · Completed · NCT04756037 - A phase 1 openlabel study to evaluate the pharmacokinetics safety and tolerability of orally administered nirmatrelvirritonavir in pregnant women with mildtomoderate COVID19
Pfizer Inc. - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.